Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: New tricks from a (not so) old drug

Expert Opinion on Investigational Drugs

Volumn 10, Issue 6, 2001, Pages 1075-1084

  Mitsiades, N ^a   Poulaki, V ^a   Mitsiades, C S ^a   Anderson, K C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Doxorubicin; FasL; Matrix metalloproteinase; MMP 7; MMPI

Indexed keywords

4 [[[4 (4 CHLOROPHENOXY)PHENYL]SULFONYL]METHYL]TETRAHYDRO 2H PYRAN 4 CARBOHYDROXAMIC ACID; 4 DEDIMETHYLAMINOSANCYCLINE; ANTINEOPLASTIC AGENT; BATIMASTAT; CASPASE 8; CGS 27023A; CIPEMASTAT; CYTOKINE; CYTOTOXIC AGENT; DOXORUBICIN; FAS ANTIGEN; FAS LIGAND; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MEMBRANE PROTEIN; NERVE GROWTH FACTOR RECEPTOR; PRINOMASTAT; REBIMASTAT; SOLIMASTAT; STROMELYSIN; TANOMASTAT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNINDEXED DRUG;

ADVANCED CANCER; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER CELL; CANCER INVASION; CELL KILLING; CELL SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DNA DAMAGE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TOLERABILITY; EMBRYO DEVELOPMENT; ENZYME INACTIVATION; ENZYME MECHANISM; EXTRACELLULAR MATRIX; GASTROINTESTINAL DISEASE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE DEFICIENCY; IN VITRO STUDY; INHIBITION KINETICS; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MORPHOGENESIS; MOUSE; MUSCULOSKELETAL DISEASE; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN TARGETING; REVIEW; TUMOR CELL; TUMOR GROWTH; TUMOR RESISTANCE; VOLUNTEER;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS; ENZYME INHIBITORS; FAS LIGAND PROTEIN; HUMANS; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASES; MEMBRANE GLYCOPROTEINS; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0034988045     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.6.1075     Document Type: Review

References (86)

1. Changing views of the role of matrix metalloproteinases in metastasis
2. Epilysin: A novel human matrix metalloproteinase (MMP-27) expressed in testis and keratinocytes and in response to injury
3. Leukolysin/MMP25/MT6-MMP: A novel matrix metalloproteinase specifically expressed in the leukocyte lineage
4. Activation mechanisms of matrix metalloproteinases
5. Coordinated expression of matrilysin during TPA-induced apoptosis of LNCaP cells: Two parallel processes affected by TPA
6. Regulation of matrilysin in the rat uterus
7. Alpha 2-macroglobulin and tissue inhibitor of metalloproteinases: Collagenase inhibitors in human preovulatory ovaries
8. Tissue inhibitors of metalloproteinases: Evolution, structure and function
9. Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts
10. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells
11. Tissue inhibitor of metalloproteinase-2 induces apoptosis in human T lymphocytes
12. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells
13. Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus. Metalloproteinase inhibition is associated with proapoptotic activity
14. TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells
15. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9)
16. Fate of melanoma cells entering the microcirculation: Over 80% survive and extravasate
17. Independence of metastatic ability and extravasation: Metastatic ras-transformed and control fibroblasts extravasate equally well
18. Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth
19. The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application
20. Molecular insights into cancer invasion: Strategies for prevention and intervention
21. Marimastat in patients with advanced pancreatic cancer: A dose-finding study
22. Ongoing trials with matrix metalloproteinase inhibitors
23. Purification and characterization of the Fas-ligand that induces apoptosis
24. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
25. Monoclonal antibody-mediated tumor regression by induction of apoptosis
26. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
27. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen
28. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis
29. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis
30. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex
31. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation
32. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity
33. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer
34. Fas and Fas ligand interactions suppress melanoma lung metastasis
35. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen
36. Development of inflammatory angiogenesis by local stimulation of Fas in vivo
37. Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis
38. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand
39. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein
40. A role for CD95 ligand in preventing graft rejection
41. Expression of Fas ligand by human cytotrophoblasts: Implications in placentation and fetal survival
42. Fas ligand-induced apoptosis as a mechanism of immune privilege
43. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
44. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain?
45. An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand
46. Constitutive expression of Fas ligand in large granular lymphocyte leukaemia
47. Fas ligand expression in nodal non-Hodgkin's lymphoma
48. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance
49. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase
50. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas
51. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
52. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion?
53. Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes
54. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer
55. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
56. Human lung carcinomas express Fas ligand
57. Fas ligand expression in thyroid carcinomas: A potential mechanism of immune evasion
58. Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors
59. Expression of the functional soluble form of human fas ligand in activated lymphocytes
60. Metalloproteinase-mediated release of human Fas ligand
61. Structural features and biochemical properties of TNF-alpha converting enzyme (TACE)
62. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha
63. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells
64. Fas ligand in human serum
65. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity
66. Downregulation of Fas ligand by shedding
67. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas
68. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
69. Fas-mediated apoptosis in seven human prostate cancer cell lines: Correlation with tumor stage
70. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug- induced apoptosis in leukemia cells
71. P53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs
72. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells
73. Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma- Irradiation-induced apoptosis of brain tumor cells
74. FasL induction and Fas upregulation by anticancer drugs
75. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity
76. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts
77. Preventive effect of matrix metalloproteinase inhibitor, R-94138, in combination with mitomycin C or cisplatin on peritoneal dissemination of human gastric cancer cell line TMK-1 in nude mice
78. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: Single agent and combination chemotherapy studies
79. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis
80. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas
81. Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma
82. Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo
83. Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation
84. Matrix metalloproteinases in multiple myeloma
85. Induction of metalloproteinase activity in human T-lymphocytes
86. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1